Top Genomics Startups in 2027

Volta Labs was spun out of MIT in 2018 with the simple mission of building biological automation from the ground up. Volta is in the proximity of Kendall Square, known as "the most innovative square mile on the planet". Being part of the open biotech culture in Kendall Square made us realize that today’s biologists are held back by the limitations of existing automation tools. With DNA sequencing in particular, we observed that the advances in DNA readout technologies had moved further along than the advances in the upstream steps of preparing samples for sequencing (sample prep). ‍ What started out as a simple printed circuit board to manipulate colored droplets at the MIT Media Lab during co-founder Udayan Umapathi’s graduate work was quickly directed toward solving the “sample prep bottleneck”. The company raised Seed Funding from top VCs in 2019 and later that year added Will Langford as a co-founder and Head of Engineering. ‍ Since then, we have been heads down in the lab inventing and building novel fluidic and sample manipulation technologies. We take an anti-disciplinary approach to solve very hard problems and weave together instrumentation, fluidics, software, biology and chemistry. While our current focus is on sequencing sample prep, we envision a new approach where a single universal machine automates most biological workflows in genomics, proteomics and synthetic biology.

Seqera empowers scientists to solve today's most complex and important challenges – from pioneering innovative therapeutics to unveiling the secrets of the universe. The journey began with Nextflow — open software that helps over 100,000 global scientists analyze and process data, with more power and flexibility than ever before. Seqera equips scientists with modern software development tools to conduct science faster, on larger datasets, and with more confidence. Accelerating discoveries in an open world.

At CancerIQ, our mission is to empower providers to offer genetic services at scale. Our solutions answer a growing problem of patient access by modeling proven systems at top academic cancer centers into a suite of digital health tools. - The CancerIQ Screening Toolkit and Navigator makes it easier for providers to efficiently identify high-risk patients, communicate that risk to patients, provide risk-based screening recommendations, and navigate them to genetic services. - The CancerIQ Self-Assessment and Specialist automates many of the tasks that are most time consuming for genetic specialists from gathering family history and running risk models, to processing test orders and generating documentation notes. - With the CancerIQ High-Risk Program and Manager providers can engage with high-risk patients over time with custom reminders to prompt follow-up activities and monitor care plans to ensure all recommendations are up to date.

Sema4 is a next-generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics. Our team creates practical tools that help patients, clinicians, and researchers better diagnose, treat, and prevent disease. We are striving to construct a more comprehensive picture of health by integrating three key elements: a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class academic research that illuminates new directions, and the pioneering information science that puts all the pieces together.

Lifebit is a leading innovator in bioinformatics software solutions and AI. In 2021, the London, UK based company closed its Series B funding round of US$60M led by Tiger Global, to fuel ongoing product innovations and global market expansion. Lifebit is pushing forward the frontiers of health and knowledge by democratising access to, and powering analyses of, omics big data. We are the pioneers revolutionising bioinformatics and biomedical data analysis. The company’s flagship product, Lifebit CloudOS, is fast becoming the industry’s standard for unified and secure research over distributed big data. On top of its core foundation, the platform provides integration to open-source analysis and visualisation tools, as well as a marketplace of proprietary ones, a powerful data and cohort browser, and advanced AI functionality that together are powering discoveries in drug discovery and vaccine development. Top tier pharmaceutical organisations, global research institutes, and bioinformatics companies the world over are deploying Lifebit CloudOS. In April 2020 we closed our Series A funding round with tremendous support from new and previous investors. Based in London, UK, Lifebit is a diverse team spanning Europe and North America, with each person empowered and involved in every aspect of the business.

Informuta is an infectious disease intelligence company that forecasts drug resistance trajectories to guide antibiotic selection with precision and quantify treatment-emergent resistance risk for the first time. Informuta uses proprietary AI and novel predictive genomic biomarkers to give clinicians the confidence to choose therapies that won’t fail their most vulnerable patients - transforming antibiotic prescribing from reactive to predictive and empowering smarter, future-proofed decisions.

Claryx is building the hospital immune system, reading the genomes of confirmed patient infections, linking related cases as outbreaks, and tracing each back to its likely source. When that source is in the building (a sink, a shared piece of equipment, a particular room), Claryx finds it by matching the patient's strain against a digital twin of the hospital's microbiome, sequenced from its air, its water and its surfaces, all on proprietary chemistry cheap enough to run continuously. Founded by brothers Kurt and Dirk Hackenberger, Claryx is based in New York and live across multiple health systems.